demonstrated that AML patients with monocytic disease are more likely to be refractory to venetoclax-based regimens because monocytic AML reduces the expression of venetoclax-targeting BCL2 while preferentially relies on MCL1 for energy metabolism and survival (14). This evidence concerns the gene MCL1 and acute myeloid leukemia.